within Pharmacolibrary.Drugs.ATC.V;

model V10XX02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0033,
    k12             = 13,
    k21             = 13
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V10XX02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ibritumomab tiuxetan (90Y) is a radiolabeled monoclonal antibody targeting the CD20 antigen on B cells. It is used as a radioimmunotherapy for treatment of certain types of non-Hodgkin's lymphoma, including relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Its use is currently limited and it is not widely approved or available in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are primarily derived from adult cancer patients with non-Hodgkin's lymphoma, both sexes, aged 18-80, without major renal or hepatic insufficiency.</p><h4>References</h4><ol><li><p>Fisher, DR, et al., &amp; Meredith, RF (2009). MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 50(4) 644–652. DOI:<a href=&quot;https://doi.org/10.2967/jnumed.108.057331&quot;>10.2967/jnumed.108.057331</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19289440/&quot;>https://pubmed.ncbi.nlm.nih.gov/19289440</a></p></li><li><p>Dahle, J, et al., &amp; Larsen, RH (2008). Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation. <i>International journal of radiation oncology, biology, physics</i> 72(1) 186–192. DOI:<a href=&quot;https://doi.org/10.1016/j.ijrobp.2008.05.029&quot;>10.1016/j.ijrobp.2008.05.029</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18722269/&quot;>https://pubmed.ncbi.nlm.nih.gov/18722269</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V10XX02;
